NEO-2734 is under clinical development by Epigene Therapeutics and currently in Phase I for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData, Phase I drugs for Chronic Myelomonocytic Leukemia (CMML) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NEO-2734’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NEO-2734 overview
NEO-2734 is relapse or refractory castration-resistant prostate cancer (CRPC), NUT midline carcinoma, chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and pancreatic cancer. It is administered orally. The drug candidate acts by targeting BET and CBP/P300. Brd4 is a bromodomain domain-4 protein which functions as a epigenetic modulator. The drug candidate is developed based on platform which consists of chemoinformatic and structure-based drug discovery.
NEO-2734 was under development for under development for the treatment of solid tumor, acute myelocytic leukemia, breast cancer, colon cancer, glioblastoma, prostate cancer, lung cancer, lymphoma, neuroblastoma, ovarian cancer, melanoma, mesothelioma.
Epigene Therapeutics overview
Epigene Therapeutics is a biotechnology company that develops small molecule-based therapeutics to treat cancer. The company is headquartered in Canada.
For a complete picture of NEO-2734’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
